loading
前日終値:
$65.42
開ける:
$65.35
24時間の取引高:
361.41K
Relative Volume:
0.15
時価総額:
$10.44B
収益:
$705.14M
当期純損益:
$-453.90M
株価収益率:
-21.54
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
+2.56%
1か月 パフォーマンス:
+53.81%
6か月 パフォーマンス:
+140.56%
1年 パフォーマンス:
+67.84%
1日の値動き範囲:
Value
$64.92
$66.03
1週間の範囲:
Value
$62.72
$66.03
52週間の値動き範囲:
Value
$23.95
$66.03

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1149)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
927
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

IONS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
65.50 10.43B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
403.99 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
608.50 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
459.88 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
768.60 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
343.08 37.42B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Sep 30, 2025

What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in

Sep 30, 2025
pulisher
Sep 30, 2025

Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Canada

Sep 30, 2025
pulisher
Sep 30, 2025

Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com

Sep 30, 2025
pulisher
Sep 29, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 03:15:49 - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

Should you hold or exit Ionis Pharmaceuticals Inc. nowQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com

Sep 28, 2025
pulisher
Sep 27, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance

Sep 27, 2025
pulisher
Sep 26, 2025

IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus

Sep 26, 2025
pulisher
Sep 26, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat

Sep 26, 2025
pulisher
Sep 26, 2025

Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat

Sep 26, 2025
pulisher
Sep 26, 2025

Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener

Sep 26, 2025
pulisher
Sep 24, 2025

Ionis chalks up rare disease win with zilganersen - The Pharma Letter

Sep 24, 2025
pulisher
Sep 24, 2025

Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK

Sep 24, 2025
pulisher
Sep 23, 2025

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com

Sep 23, 2025
pulisher
Sep 23, 2025

Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq

Sep 23, 2025
pulisher
Sep 23, 2025

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen

Sep 23, 2025
pulisher
Sep 23, 2025

A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm

Sep 23, 2025
pulisher
Sep 23, 2025

Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News

Sep 23, 2025
pulisher
Sep 23, 2025

Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits

Sep 23, 2025
pulisher
Sep 23, 2025

Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace

Sep 23, 2025
pulisher
Sep 23, 2025

IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace

Sep 23, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga

Sep 22, 2025
pulisher
Sep 22, 2025

Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis' brain disorder drug shows promise in clinical trial - TradingView

Sep 22, 2025
pulisher
Sep 22, 2025

Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.Weekly Stock Recap & Weekly Return Optimization Alerts - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis and Sobi’s Tryngolza gains approval in EU for FCS treatment - Yahoo Finance

Sep 22, 2025

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$35.80
price up icon 1.62%
$85.78
price up icon 1.20%
$31.39
price up icon 2.31%
$102.62
price up icon 4.05%
$144.32
price up icon 0.43%
biotechnology ONC
$343.34
price up icon 0.53%
大文字化:     |  ボリューム (24 時間):